Dose dependence of efficacy but not of safety in sublingual immunotherapy

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 65, Issue 1, 2006, Pages 38-40

  Frati, Franco ^a,c,e   Incorvaia, C ^b   Marcucci, F ^a   Sensi, L ^a   Di Cara, G ^a   Puccinelli, P ^c   Dal Bo, S ^d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c Scientific Department   (Italy)

^d Private Allergy Practice ^*  (Italy)

^e NONE   (Italy)

Author keywords

Asthma; Rhinitis; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT; PLACEBO; RAGWEED ANTIGEN;

ANAPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPERIMENTAL STUDY; EXPOSURE; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; INTERNALIZATION; LOW DRUG DOSE; REVIEW;

EID: 33646422219     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2006.584     Document Type: Review

References (25)

1. Committee on Safety in Medicine. CSM update: desensitizing vaccines. BMJ 1986: 293: 948.
2. Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 79: 660-77.
3. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111: 437-48.
4. Malling HJ, Weeke B (eds). Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology. Allergy 1993; 48 (suppl 14): 9-35.
5. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl 54): 4-30.
6. Wilson DR, Torres-Lima M, Durham S. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60: 4-12.
7. Bousquet J, van Cauwenberge P (eds). WHO initiative. Allergic rhinitis and its impact on asthma (ARIA). J Allergy Clin Immunol 2001; 108 (suppl 5): 147-334.
8. André C, Perrin-Fayolle M, Grosclaude M, et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131: 111-8.
9. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of subligual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93: 425-430.
10. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double blind, double dummy study. Allergy 2004; 59: 45-53.
11. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60: 952-6.
12. Van Metre TE, Adkinson NF Jr. Immunotherapy for aeroallergen disease. In Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW (eds): Allergy. Principles and practice. St. Louis, Mosby-Year Book 1993: 1489-1509.
13. Turkeltaub PC. The importance of allergen dose on the safety and efficacy of immunotherapy of ragweed hay fever with standardized short ragweed extract. J Allergy Clin Immunol 1986; 77: 211-16.
14. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. a double-blind study. Allergol Immunopathol 1990; 18: 277-84.
15. Horack F, Stubner P, Berger UE, et al. Immunotherapy with sublingual birch pollen extract. a short-term double-blind placebo study. J Invest Allergol Clin Immunol 1998; 8: 165-71.
16. Voltolini S, Modena P, Minale P, et al. Sublingual Immunotherapy in tree pollen allergy. Double-Blind, Placebo-Controlled Study with a biologically standardised extract of three pollen (Alder, Birch, And Hazel) administered by a Rush Schedule. Allergol Immunopathol 2001; 29: 103-10.
17. Andé C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121: 229-234.
18. Clavel R, Bousquet J, André C. Clinical Efficacy of sublingual-swallow immunotheraphy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998; 53: 493-8.
19. Gidaro G, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingaal-swahow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35: 565-71.
20. Pastorello EA, Incorvaia C, Ortolani C. The mouth and pharynx. In Ortolani C (Ed): Atlas on mechanisms in adverse reactions to foods. Allergy 1995; 50 (Suppl 20): 41-44.
21. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999; 54: 1110-13.
22. Fiocchi A, Pajno GB, La Grutta S, et al. Safety of sublingual immunotherapy in children aged less than 6 years. Ann Allergy Asthma Immunol 2005; 95: 254-58.
23. Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans cell type with high constitutive Fcepsilon RI expression. J Allergy Clin Immunol 2003; 112: 141-48.
24. Groux H, Fournier N, Cottrez F. Role of dendritic cells in the generation of regulatory T cells. Semin Immunol 2004; 16: 99-106.
25. Noirey N, Rougier N, André C, Schmitt D, Vincent C. Langerhans-like dendritic cefls generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol 2000; 105: 1194-201.